TheraRadar
← Back
Data updated: Mar 29, 2026

EXELIXIS

OncologyMetabolicGastroenterology
Pharma

EXELIXIS is a pharmaceutical company focused on Oncology, Metabolic, Gastroenterology. Key products include CABOMETYX.

2012
Since
2
Drugs
-
Trials
4
Approved (2yr)

Key Drugs

CABOMETYX
cabozantinib s-malate
AXL 5 indications · 2016
COMETRIQ
cabozantinib s-malate
AXL 1 indications · 2012

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

COMETRIQ 2025-10-09
Labeling
CABOMETYX 2025-10-09
Labeling
CABOMETYX 2025-09-10
Efficacy
CABOMETYX 2025-03-26
Efficacy
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 77%
1 drugs Phase 3: 6 Phase 2: 2 Phase 1: 13
Metabolic 20%
1 drugs Phase 3: 1 Phase 1: 2
Gastroenterology 3%
0 drugs Phase 1: 2

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Takeda big-pharma
Oncology, Gastroenterology, Metabolic
Pfizer big-pharma
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology, Metabolic
Amgen biotech
Oncology, Metabolic, Gastroenterology
EMD SERONO INC biotech
Oncology, Metabolic, Gastroenterology